UBS lowered the firm’s price target on Bio-Rad (BIO) to $335 from $350 and keeps a Buy rating on the shares. While there were some bright spots, margins were “messy,” and the process chrom headwind was bigger than expected, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: